Verantwoord innoveren

GMO safety
Synthetic biology
Adaptive Risk Assessment

People with the genetic disease Duchenne muscular dystrophy cannot synthesize dystrophin, a component of the scaffolding inside muscle cells. This deficiency results in muscle wasting and early death. The CRISPR–Cas9 gene-editing system has previously been used to trigger dystrophin production in mice. A team of scientists at the University of Texas Southwestern Medical Center in Dallas sought to test the technique in dogs. The researchers treated four dogs — all lacking dystrophin because of a genetic mutation — with the CRISPR–Cas9 system, which snipped out a short stretch of the animals’ DNA. This allowed the dogs’ cells to make dystrophin. Levels of the protein in one dog’s heart muscle reached 92% of normal.


Source: Nature, 31 August 2018.


​​ Kantoor:
+31 (0)343 51 47 61
+31 (0)6 238 68 017

Diederichslaan 25
3971 PA Driebergen